S&P 500   5,254.35 (+0.11%)
DOW   39,807.37 (+0.12%)
QQQ   444.52 (-0.07%)
AAPL   171.95 (-0.78%)
MSFT   421.16 (-0.06%)
META   488.67 (-1.05%)
GOOGL   151.05 (+0.12%)
AMZN   180.33 (+0.28%)
TSLA   175.57 (-2.37%)
NVDA   903.95 (+0.16%)
NIO   4.50 (-3.64%)
AMD   179.98 (+0.22%)
BABA   72.43 (+1.17%)
T   17.64 (+0.51%)
F   13.28 (+1.68%)
MU   117.73 (-1.18%)
CGC   8.49 (-11.10%)
GE   176.02 (-2.28%)
DIS   122.44 (+1.21%)
AMC   3.72 (-14.29%)
PFE   27.81 (+0.11%)
PYPL   66.99 (+0.63%)
XOM   116.22 (+1.09%)
S&P 500   5,254.35 (+0.11%)
DOW   39,807.37 (+0.12%)
QQQ   444.52 (-0.07%)
AAPL   171.95 (-0.78%)
MSFT   421.16 (-0.06%)
META   488.67 (-1.05%)
GOOGL   151.05 (+0.12%)
AMZN   180.33 (+0.28%)
TSLA   175.57 (-2.37%)
NVDA   903.95 (+0.16%)
NIO   4.50 (-3.64%)
AMD   179.98 (+0.22%)
BABA   72.43 (+1.17%)
T   17.64 (+0.51%)
F   13.28 (+1.68%)
MU   117.73 (-1.18%)
CGC   8.49 (-11.10%)
GE   176.02 (-2.28%)
DIS   122.44 (+1.21%)
AMC   3.72 (-14.29%)
PFE   27.81 (+0.11%)
PYPL   66.99 (+0.63%)
XOM   116.22 (+1.09%)
S&P 500   5,254.35 (+0.11%)
DOW   39,807.37 (+0.12%)
QQQ   444.52 (-0.07%)
AAPL   171.95 (-0.78%)
MSFT   421.16 (-0.06%)
META   488.67 (-1.05%)
GOOGL   151.05 (+0.12%)
AMZN   180.33 (+0.28%)
TSLA   175.57 (-2.37%)
NVDA   903.95 (+0.16%)
NIO   4.50 (-3.64%)
AMD   179.98 (+0.22%)
BABA   72.43 (+1.17%)
T   17.64 (+0.51%)
F   13.28 (+1.68%)
MU   117.73 (-1.18%)
CGC   8.49 (-11.10%)
GE   176.02 (-2.28%)
DIS   122.44 (+1.21%)
AMC   3.72 (-14.29%)
PFE   27.81 (+0.11%)
PYPL   66.99 (+0.63%)
XOM   116.22 (+1.09%)
S&P 500   5,254.35 (+0.11%)
DOW   39,807.37 (+0.12%)
QQQ   444.52 (-0.07%)
AAPL   171.95 (-0.78%)
MSFT   421.16 (-0.06%)
META   488.67 (-1.05%)
GOOGL   151.05 (+0.12%)
AMZN   180.33 (+0.28%)
TSLA   175.57 (-2.37%)
NVDA   903.95 (+0.16%)
NIO   4.50 (-3.64%)
AMD   179.98 (+0.22%)
BABA   72.43 (+1.17%)
T   17.64 (+0.51%)
F   13.28 (+1.68%)
MU   117.73 (-1.18%)
CGC   8.49 (-11.10%)
GE   176.02 (-2.28%)
DIS   122.44 (+1.21%)
AMC   3.72 (-14.29%)
PFE   27.81 (+0.11%)
PYPL   66.99 (+0.63%)
XOM   116.22 (+1.09%)
NASDAQ:ADXS

Ayala Pharmaceuticals (ADXS) Stock Price, News & Analysis

$0.64
-0.06 (-8.57%)
(As of 03:03 PM ET)
Today's Range
$0.64
$0.72
50-Day Range
$0.52
$1.31
52-Week Range
$0.51
$1.95
Volume
16,416 shs
Average Volume
25,718 shs
Market Capitalization
$6.88 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ADXS stock logo

About Ayala Pharmaceuticals Stock (NASDAQ:ADXS)

Ayala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia. Ayala Pharmaceuticals, Inc. is based in Wilmington, Delaware.

ADXS Stock Price History

ADXS Stock News Headlines

AI to Meet the Same Fate as EVs?
When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11…
IMNM Oct 2024 22.500 call
IMNM Oct 2024 25.000 call
IMNM Oct 2024 25.000 put
IMNM Oct 2024 45.000 call
AI to Meet the Same Fate as EVs?
When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11…
Ayala Pharmaceuticals Inc Ordinary Shares ADXS
Ayala Pharmaceuticals Inc (ADXS)
Armando Ayala
See More Headlines
Receive ADXS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ayala Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
9/09/2021
Today
3/28/2024
Next Earnings (Estimated)
5/21/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:ADXS
Employees
N/A
Year Founded
N/A

Profitability

Pretax Margin
-210,876.91%

Debt

Sales & Book Value

Annual Sales
$3.24 million
Book Value
($0.61) per share

Miscellaneous

Free Float
10,684,000
Market Cap
$7.30 million
Optionable
Not Optionable
Beta
1.65
5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Dr. Ruth Ben Yakar Ph.D. (Age 54)
    Chief Exec. Officer
  • Dr. Stela Gangrenovitch Ph.D.
    Co-Founder, Chief Scientist Officer and Director
  • Mr. Mark Gengrinovitch LLB
    Co-Founder, Chief Financial Officer and Director

ADXS Stock Analysis - Frequently Asked Questions

Should I buy or sell Ayala Pharmaceuticals stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ayala Pharmaceuticals in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" ADXS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ADXS, but not buy additional shares or sell existing shares.
View ADXS analyst ratings
or view top-rated stocks.

How have ADXS shares performed in 2024?

Ayala Pharmaceuticals' stock was trading at $0.6670 at the beginning of 2024. Since then, ADXS stock has decreased by 4.0% and is now trading at $0.64.
View the best growth stocks for 2024 here
.

When is Ayala Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 21st 2024.
View our ADXS earnings forecast
.

How were Ayala Pharmaceuticals' earnings last quarter?

Ayala Pharmaceuticals, Inc. (NASDAQ:ADXS) posted its quarterly earnings data on Thursday, September, 9th. The company reported ($0.02) EPS for the quarter, topping analysts' consensus estimates of ($0.04) by $0.02. The firm earned $0.25 million during the quarter.

What other stocks do shareholders of Ayala Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Ayala Pharmaceuticals investors own include Inovio Pharmaceuticals (INO), Madrigal Pharmaceuticals (MDGL), Merck & Co., Inc. (MRK), Anavex Life Sciences (AVXL), Vistagen Therapeutics (VTGN), Novavax (NVAX), Highpower International (HPJ), OPKO Health (OPK) and Athersys (ATHX).

How do I buy shares of Ayala Pharmaceuticals?

Shares of ADXS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ADXS) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners